|Go to market news section|
Friday 30th November 2012
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
Payment of US$15 million contingent DermaPet® consideration
The Company announces that, pursuant to the terms of the DermaPet Purchase Acquisition Agreement dated 22 October 2010 (the "Agreement"), a payment in the sum of US$15 million (£9.4 million) has been paid to the vendors. The payment was triggered by the rolling 12 monthly revenue from the sale of DermaPet products exceeding US$15 million in October 2012. The achievement of this target, ahead of Company expectations, demonstrates the success of the acquisition.
The payment was made in cash from existing facilities.
In line with the Agreement a further payment of US$5 million will become due if, at any time in the next four years, the rolling 12 monthly revenue exceeds US$20 million.
Ian Page, Chief Executive
00 44 1782 771100
Dechra is an international veterinary pharmaceutical business. Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
|©London Stock Exchange plc. All rights reserved|